Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF

Applied Biochemistry and Biotechnology

Volumn 176, Issue 7, 2015, Pages 1985-1995

  Ebrahimizadeh, Walead ^a,b   Mousavi Gargari, Seyed Latif Mousavi ^b   Javidan, Zahra ^b   Rajabibazl, Masoumeh ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Cancer; Phage display; VEGF; VHH nanobody

Indexed keywords

ANTIBODIES; BINDING ENERGY; BINS; CELL ENGINEERING; CLONING; DISEASES; ONCOLOGY; POLYMERASE CHAIN REACTION; TUMORS; UREA;

ANGIOGENESIS; CANCER; NANOBODY; PHAGE DISPLAY; VEGF;

ENDOTHELIAL CELLS;

COMPLEMENTARY DNA; NANOBODY; RECOMBINANT VASCULOTROPIN; UREA; VASCULOTROPIN A; PEPTIDE LIBRARY; RECOMBINANT PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ARTICLE; BINDING SITE; BIOPANNING; CAMEL; CONTROLLED STUDY; ENTEROBACTERIA PHAGE M13; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MALE; MOLECULAR CLONING; NONHUMAN; PH; PHAGE DISPLAY; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RECEPTOR BINDING; THERMOSTABILITY; ANIMAL; CHEMISTRY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PEPTIDE LIBRARY; PROCEDURES; SOLUBILITY;

ANIMALS; BACTERIOPHAGE M13; BINDING SITES; CAMELS; GENETIC ENGINEERING; IMMUNIZATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SINGLE-DOMAIN ANTIBODIES; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939259648     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-015-1695-y     Document Type: Article

References (37)

1. Hicklin, D. J., & Ellis, L. M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011–1027.
2. Schlaeppi, J.-M., & Wood, J. M. (1999). Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer and Metastasis Reviews, 18, 473–481.
3. Ferrara, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Seminars in Oncology, 29, 10–14.
4. Awata, T., Inoue, K., Kurihara, S., Ohkubo, T., Watanabe, M., Inukai, K., Inoue, I., & Katayama, S. (2002). A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes, 51, 1635–1639.
5. Carmeliet, P. (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology, 69, 4–10.
6. Hirakawa, S., Kodama, S., Kunstfeld, R., Kajiya, K., Brown, L. F., & Detmar, M. (2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. The Journal of Experimental Medicine, 201, 1089–1099.
7. Ishigami, S., Arii, S., Furutani, M., Niwano, M., Harada, T., Mizumoto, M., Mori, A., Onodera, H., & Imamura, M. (1998). Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. British Journal of Cancer, 78, 1379.
8. Fuh, G., Wu, P., Liang, W.-C., Ultsch, M., Lee, C. V., Moffat, B., & Wiesmann, C. (2006). Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin™ Fab. Journal of Biological Chemistry, 281, 6625–6631.
9. Lien, S., & Lowman, H. B. (2008). In therapeutic anti-VEGF antibodies (vol 181 p 6). Berlin Heidelberg: Springer.
10. Behdani, M., Zeinali, S., Khanahmad, H., Karimipour, M., Asadzadeh, N., Azadmanesh, K., Khabiri, A., Schoonooghe, S., Habibi Anbouhi, M., & Hassanzadeh-Ghassabeh, G. (2012). Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Molecular Immunology, 50, 35–41.
11. Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., & Kozin, S. V. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 10, 145–147.
12. Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998). VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure, 6, 1153–1167.
13. Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., & De Vos, A. M. (1997). Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proceedings of the National Academy of Sciences, 94, 7192–7197.
14. Deffar, K., Shi, H., Li, L., Wang, X., & Zhu, X. (2009). Nanobodies-the new concept in antibody engineering. African Journal of Biotechnology, 8, 2645–2652.
15. Ferrari, A., Rodriguez, M., Power, P., Weill, F., De Simone, E., Gutkind, G., & Leoni, J. (2007). Immunobiological role of llama heavy-chain antibodies against a bacterial β-lactamase. Veterinary Immunology and Immunopathology, 117, 173–182.
16. Harmsen, M., & De Haard, H. (2007). Properties, production, and applications of camelid single-domain antibody fragments. Applied Microbiology and Biotechnology, 77, 13–22.
17. Muyldermans, S., Baral, T., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V., & Revets, H. (2009). Camelid immunoglobulins and nanobody technology. Veterinary Immunology and Immunopathology, 128, 178–183.
18. Ebrahimizadeh, W., & Rajabibazl, M. (2014). Bacteriophage vehicles for phage display: biology, mechanism, and application. Current Microbiology, 69, 109–120.
19. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248–254.
20. Ardekani, L.S., Gargari, S.L.M., Rasooli, I., Bazl, M.R., Mohammadi, M., Ebrahimizadeh, W., Bakherad, H., Zare, H. (2013). A novel nanobody against urease activity of Helicobacter pylori. International Journal of Infectious Diseases,
21. Bakherad, H., Mousavi Gargari, S. L., Rasooli, I., Rajabibazl, M., Mohammadi, M., Ebrahimizadeh, W., Safaee Ardakani, L., & Zare, H. (2013). In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Molecular Biotechnology, 55, 159–167.
22. Ebrahimizadeh, W., Gargari, S. M., Rajabibazl, M., Ardekani, L. S., Zare, H., & Bakherad, H. (2013). Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Applied Microbiology and Biotechnology, 97, 4457–4466.
23. Araste, F., Ebrahimizadeh, W., Rasooli, I., Rajabibazl, M., & Gargari, S. L. M. (2014). A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis. Biotechnology Letters, 36, 21–28.
24. Beatty, J. D., Beatty, B. G., & Vlahos, W. G. (1987). Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. Journal of Immunological Methods, 100, 173–179.
25. Kolkman, J. A., & Law, D. A. (2010). Nanobodies—from llamas to therapeutic proteins. Drug Discov Today Tech., 7, e139–e146.
26. Ferrara, N., Hillan, K. J., & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 333, 328–335.
27. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation, 105, R15.
28. Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminar in Oncology, 29, 15–18.
29. Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007). VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine, 13, 223–230.
30. Shojaei, F. (2012). Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Letters, 320, 130–137.
31. Samant, R. S., & Shevde, L. A. (2011). Recent advances in anti-angiogenic therapy of cancer. Oncotarget, 2, 122.
32. Eichelberg, C., Heuer, R., Chun, F. K., Hinrichs, K., Zacharias, M., Huland, H., & Heinzer, H. (2008). Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. European Urology, 54, 1373–1378.
33. Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., & Morgan, J. A. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet, 368, 1329–1338.
34. Ellis, L. M., & Hicklin, D. J. (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer, 8, 579–591.
35. Ferreira, L. M. R. (2010). Cancer metabolism: the Warburg effect today. Experimental and Molecular Pathology, 89, 372–380.
36. Berg, J. M., T.J., Stryer, L. (2002). Biochemistry, 5th edn. In section 33.3, antibodies bind specific molecules through their hypervariable loops. New York: W H Freeman.
37. Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., & Scheuplein, F. (2009). Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Medical Microbiology and Immunology, 198, 157–174.